Release Date: August 04, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Leidos Holdings Inc LDOS reported record Q2 revenue of $4.6 billion, up 7% year-over-year, with a best-in-class adjusted EBITDA margin of 13.8%.
- The company raised its full-year 2026 guidance for revenue, EPS, and operating cash flow, reflecting strong portfolio performance and confidence in its North Star 2030 strategy.
- Defense segment delivered exceptional results with a 2.2 book-to-bill ratio in Q2 and a 1.9 trailing twelve-month ratio, driven by major wins in munitions, unmanned surface vessels, and space payloads.
- Operating cash flow reached a Q2 record of nearly $800 million, and the company paid down the remaining $300 million of commercial paper, ending the quarter with a strong balance sheet and gross leverage of 2.5 times.
- The company is diversifying its earnings power, with the rest of Leidos (excluding health) expected to grow approximately 7% in revenues and 19% in adjusted EBITDA in 2026, supported by growth pillars in defense tech, energy, and cyber.
- Customer procurement activity is accelerating, with a $23 billion proposal pipeline and a $12 billion defense tech opportunity pipeline over the next 12 months, positioning the company for continued bookings momentum.
Negative Points
- The VA has suspended incentive payments for the medical disability exam business for the rest of 2026, impacting health segment revenue and margins, though the company has incorporated this into its guidance.
- Health segment revenues contracted in Q2 due to the full incorporation of a fourth vendor on the VBA Medical Disability Examination Regions contract, with expectations of sustained lower revenue levels for the rest of the year.
- The MHS Genesis program faces uncertainty as the DHA plans to procure software directly from commercial vendors and potentially insource systems integration, reducing Leidos' role in future phases.
- The company anticipates a potential government shutdown or continuing resolution after the midterms, which could disrupt award activity and revenue timing in the intel and digital segments.
- M&A targets are currently expensive relative to Leidos' own valuation, limiting the company's ability to make accretive acquisitions and potentially constraining growth through inorganic means.
Q & A Highlights
Q: Can you provide more clarity on the VBA medical disability exam (MDE) business, specifically the suspension of incentive payments and what this means for 2027 margins and the upcoming re-compete?
A: Tom Bell (CEO) explained that the VA decided to suspend incentive payments for all vendors for the rest of 2026 due to administrative and auditability issues. He noted that this is a 2026-only pause and that the VA remains focused on quality, veteran experience, and cost. While a draft RFP for the re-compete has not been issued, he expects incentives to be part of the future contract. The company has been informed of likely extensions for the current regions contract (up to six months into 2027) and a one-year extension for international and pre-discharge work. The Q4 2026 run rate is a good baseline for 2027, and the company believes it is well-positioned to win the re-compete.
Q: Regarding the MHS Genesis (DIM SUM) program, why is the Defense Health Agency (DHA) planning to do integration internally, and is this a one-off situation or a broader trend of limiting systems integrators?
A: Tom Bell (CEO) acknowledged a broader trend of insourcing systems integration across government agencies, driven by the administration's desire to acquire commercial technology directly. However, he emphasized that Leidos can transition its value-added services to higher-level mission systems integration. For MHS Genesis, there is still a need for Leidos to maintain, enhance, and partner on the system. Chris (CFO) added that the customer lacks the capacity to take over all activities, so there is a good chance Leidos perpetuates its support role while the future structure becomes clearer.
Q: Can you discuss the cadence of award activity, particularly for the intelligence and digital business, and the opportunity to exit the government fiscal year with higher backlog?
A: Tom Bell (CEO) stated that customer procurement activity is accelerating, evidenced by a solid 1.1 book-to-bill ratio for the quarter and a 2.2 ratio in the Defense segment. He cited the administration's push to put unobligated funds on contract before October 1, which supports second-half bookings. He mentioned a $23 billion pipeline of proposals that could be adjudicated over the next 3-12 months, aligning with customer priorities in space, maritime, and munitions.
Q: How is the mix of fixed-price contracts evolving in the intelligence and digital segment, and how quickly will this change?
A: Tom Bell (CEO) noted that customers are frequently approaching Leidos with unsolicited requests to convert work to fixed-price contracts, a conversation the company welcomes. This aligns with the administration's preference for outcome-based results. He highlighted Leidos' investments in full-spectrum cyber and a new partnership with CoreWeave to provide sovereign AI capabilities, which are well-suited for fixed-price, outcome-based contracting. Chris (CFO) added that the fixed-price percentage of work is increasing and plays to Leidos' strengths, especially with new software tools like Parkata.
Q: What is the outlook for the defense business, including the addition of more hardware in the mix and its impact on margins?
A: Tom Bell (CEO) expressed strong bullishness for the defense tech business, expanding growth engines to include munitions and counter-UAS capabilities. He highlighted the IFPC program hitting full stride, the small cruise missile (AGM-190A/Havoc Spear) undergoing successful flight tests, and the LCCM framework on track for full-rate production. He cited a $44 billion addressable market for low-cost containerized munitions over the next 10 years. Chris (CFO) added that margins are improving as programs mature, with each tranche of space payloads showing higher profitability. Tom also mentioned a $12 billion pipeline of visible opportunities in the next 12 months.
Q: Can you elaborate on the free cash flow trends and the key levers to achieve high single-digit to low double-digit growth?
A: Chris (CFO) highlighted a record Q2 with $793 million in operating cash flow and $761 million in free cash flow. He noted the company raised full-year free cash flow guidance by $150 million due to reduced CapEx expectations (closer to $250 million). The Enterprise Transformation Office is working on reducing days sales outstanding (DSO), which presents future upside. Tom Bell (CEO) reiterated the company's low capital intensity philosophy, with growth pillars in defense tech, energy, and cyber perpetuating high cash conversion.
Q: How are you balancing growth investments, M&A, and share repurchases given the healthy balance sheet and current valuation?
A: Tom Bell (CEO) outlined a balanced capital allocation approach. While CapEx has increased this year to seize defense tech opportunities, this is a point-in-time expectation, with 1.5% capital intensity as the norm. The Board authorized a new $20 million share repurchase program. He noted that M&A targets are currently expensive while Leidos' valuation is not, so the company will be prudent. Chris (CFO) added that there is significant capacity to deploy capital and the company agrees the valuation is not where it should be, working hard to correct that.
Q: What is the nature of the $12 billion pipeline of defense tech opportunities, and are they new or re-compete contracts?
A: Tom Bell (CEO) explained that the pipeline includes follow-ons to existing programs and new contracts. Specific opportunities include the Navy's Medium Unmanned Surface Vessel program, the DDG(X) battleship design, small cruise missile and LCCM production contracts, and counter-UAS capabilities. He highlighted the growth of the Huntsville workforce by 13% this year, with 33% in manufacturing, indicating a strong push into scaled production.
Q: With the removal of VBA incentives, what is a good baseline for profitability in F2026 and F2027, and how should we think about the transition of VBA and DIM SUM?
A: Tom Bell (CEO) stated that the Q4 2026 performance of the MDE business is a good jumping-off point for 2027. He emphasized the VA's focus on quality and veteran experience, which plays to Leidos' strengths. Chris (CFO) added that job one is to resecure the franchise, absorbing back-half headwinds, and then leveraging the platform (15,000 providers, 90 clinics, 2.8 million exams annually) for growth in behavioral health and rural
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
